Bristol-Myers Squibb

Senior Institutional Mental Health Account Specialist, Neuroscience – COBENFY – Tampa, FL

Tampa, Florida, United States

Auto‑apply with AI Apply

$60,000 – $90,000Compensation

Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical Sales, Healthcare, Mental HealthIndustries

Requirements

Candidates should possess a Bachelor’s degree in a related field, such as Pharmacy, Nursing, or a scientific discipline, and have at least 5 years of experience in institutional mental health, preferably with a focus on neuroscience or pharmaceutical sales. Strong knowledge of the healthcare landscape, particularly within community mental health centers and hospitals, is essential. Demonstrated ability to build and maintain relationships with key opinion leaders and healthcare providers is also required.

Responsibilities

The Senior Institutional Mental Health Account Specialist will be responsible for driving demand for BMS medicines within the designated territory, primarily focusing on Community Mental Health Centers, Certified Community Behavior Health Centers, and Hospitals. This includes engaging with HCPs through differentiated Customer Experiences, conducting scientific dialogue, and ensuring on-label discussions. The role involves building and maintaining strong professional credibility with regional thought leaders, and collaborating with the hospital launch team to support the commercialization of COBENFY.

Skills

Healthcare Landscape

Community Mental Health Centers

Hospitals

Key Opinion Leaders

Healthcare Providers

Scientific Dialogue

Commercialization

Relationship Building

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free